Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Urethritis, Cystitis, Pyelonephritis), By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 636.57 Million
CAGR (2026-2031)	4.21%
Fastest Growing Segment	Cystitis
Largest Market	North America
Market Size (2031)	USD 815.27 Million

Market Overview

The Global Urinary Tract Infection Testing Market will grow from USD 636.57 Million in 2025 to USD 815.27 Million by 2031 at a 4.21% CAGR. The Global Urinary Tract Infection Testing Market encompasses a range of diagnostic procedures, including urinalysis, urine culture, and molecular diagnostics, designed to detect and identify pathogens within the urinary system. The market is primarily propelled by the rising global prevalence of urinary tract infections, particularly among the geriatric population and women, alongside an increasing incidence of hospital-acquired infections such as catheter-associated cases. Furthermore, the growing demand for rapid point-of-care testing solutions to facilitate immediate treatment decisions is significantly accelerating market adoption. According to the American Urological Association, in 2024, it is estimated that 150 million urinary tract infections occur yearly worldwide, accounting for 6 billion dollars in health care expenditures.

Despite these strong growth indicators, the market faces a significant challenge regarding the diagnostic accuracy of conventional rapid screening methods. Standard urine dipstick tests often exhibit low sensitivity and specificity, leading to high rates of false negatives or false positives that can result in untreated infections or unnecessary antibiotic prescriptions. This limitation necessitates reliance on time-consuming urine cultures for confirmation, thereby delaying effective treatment and potentially hindering the widespread expansion of rapid diagnostic adoption in cost-sensitive healthcare settings.

Key Market Drivers

The Escalating Global Prevalence of Urinary Tract Infections acts as a primary catalyst for the market, necessitating high-volume diagnostic capabilities across healthcare settings. This driver is intensified by the growing burden of antimicrobial resistance (AMR), which complicates empirical treatment and mandates precise pathogen identification. As standard antibiotic regimens become less effective against resistant strains, the clinical reliance on accurate screening and culture confirmation has intensified to prevent progression to pyelonephritis or urosepsis. According to the U.S. Food and Drug Administration (FDA), October 2024, in the 'FDA approves new treatment for uncomplicated urinary tract infections' announcement, approximately one-half of all women will experience at least one uncomplicated urinary tract infection in their lifetime. This widespread susceptibility ensures a consistent, escalating demand for diagnostic testing services to manage both acute and recurrent cases effectively.

Simultaneously, the Rapid Proliferation of Point-of-Care Testing Technologies is transforming the market by addressing the critical need for speed and diagnostic precision. Healthcare providers are increasingly shifting away from traditional methods that require days for results, favoring molecular and rapid phenotypic tests that support immediate clinical decision-making. According to the Centers for Disease Control and Prevention (CDC), November 2024, in the 'Antibiotic Use and Stewardship in the United States, 2024 Update', the number of Medicare claims for multiplex molecular tests for urinary tract infections increased over a 50-fold between 2016 and 2023. This dramatic surge underscores the market's pivot toward advanced diagnostics. Furthermore, innovation in rapid susceptibility testing is accelerating this trend; according to bioMérieux, in 2024, the newly cleared VITEK REVEAL AST System can deliver actionable results for specific gram-negative bacteria in an average of 5.5 to 6 hours, significantly optimizing the timeframe for targeted therapeutic interventions.

Download Free Sample Report

Key Market Challenges

The primary impediment hampering the growth of the Global Urinary Tract Infection Testing Market is the insufficient diagnostic accuracy inherent in conventional rapid screening methods. While urine dipstick tests are widely utilized for their speed and low cost, they frequently fail to provide the sensitivity and specificity required for definitive clinical diagnoses. This technological limitation forces healthcare providers to depend on time-consuming urine cultures to verify results, thereby negating the immediacy of point-of-care benefits. Consequently, the market struggles to fully transition toward decentralized testing models because clinicians cannot confidently base treatment decisions solely on rapid diagnostics that are prone to errors.

This lack of precision creates significant operational inefficiencies and clinical risks that restrain market potential. High rates of false-positive results often lead to unnecessary antibiotic administration, while false negatives result in delayed interventions for patients requiring urgent care. The severity of this diagnostic gap is evident in recent clinical data. According to the American Urological Association, in 2025, standard urinalysis indicators such as positive leukocyte esterase and nitrites exhibited positive predictive values lower than 50% for identifying actual urinary tract infections. Such data confirms that existing rapid tools often fail to distinguish between infection and contamination, compelling healthcare systems to maintain expensive, labor-intensive reference laboratory workflows that slow overall market throughput.

Key Market Trends

The rapid expansion of home-based and self-testing ecosystems is fundamentally reshaping the Global Urinary Tract Infection Testing Market by decentralizing access to care and alleviating the burden on primary clinical settings. This trend is characterized by the increasing availability of direct-to-consumer diagnostic kits and pharmacy-led testing services, which allow patients to obtain rapid screening and immediate treatment without visiting a general practitioner. The shift is particularly evident in regions implementing policy changes to empower community pharmacists, thereby creating a new, high-volume channel for market growth outside traditional hospitals. According to The Pharmacist, April 2025, in the 'Almost five million Pharmacy First consultations delivered in first year' article, between February 2024 and January 2025, there were 607,646 uncomplicated urinary tract infection consultations delivered via the Pharmacy First service in England, highlighting the massive consumer adoption of decentralized testing pathways.

Simultaneously, the market is experiencing a significant shift towards molecular and genomic diagnostic methods, driven by the critical need to overcome the performance limitations of standard microbiological techniques. While traditional methods remain common, their inability to detect fastidious organisms or provide rapid antimicrobial susceptibility profiles has accelerated the integration of next-generation sequencing (NGS) and advanced genomic platforms into routine diagnostic workflows. These sophisticated technologies offer superior sensitivity and specificity, enabling the precise identification of pathogens that conventional cultures frequently miss, thus mitigating the risk of recurrent infections and ineffective antibiotic prescribing. According to Biotia, September 2025, in the 'Biotia Announces Advanced Test to Treat Offering for Recurrent Urinary Tract Infections' announcement, standard urine culture fails about 30% of the time, a diagnostic gap that is actively propelling the clinical transition toward more reliable genomic-based testing solutions.

Segmental Insights

The Cystitis segment is the fastest-growing category in the Global Urinary Tract Infection Testing Market due to the increasing prevalence of bladder inflammation among the aging population. This segment benefits from a high volume of recurrent cases which necessitate frequent diagnostic screening to manage patient health effectively. Additionally, guidelines from the Centers for Disease Control and Prevention regarding catheter-associated infections encourage rigorous testing protocols to prevent further health complications. Consequently, the rising demand for prompt and accurate detection of lower urinary tract infections sustains the rapid expansion of this specific market segment.

Regional Insights

North America maintains a dominant position in the Global Urinary Tract Infection Testing Market, primarily driven by the rising incidence of urinary infections and a well-established healthcare infrastructure. This leadership is reinforced by the strong presence of major diagnostic manufacturers and increasing awareness regarding early disease detection. Furthermore, supportive regulatory frameworks provided by the U.S. Food and Drug Administration encourage the development and commercialization of new diagnostic solutions. These combined factors ensure consistent market expansion across the region, establishing it as the primary contributor to the global industry.

Recent Developments

• In November 2024, Biotia announced that it received regulatory approval from the New York State Department of Health for its genomics-based urine test. This laboratory-developed test leverages artificial intelligence and next-generation sequencing to identify a broad range of urogenital pathogens and antimicrobial resistance markers. The approval marks a significant advancement in diagnostic capabilities, offering higher sensitivity and specificity compared to traditional culture methods. This breakthrough is particularly valuable for diagnosing complicated or recurrent infection cases where standard testing frequently fails to detect the causative agent, thus enabling more personalized patient care.
• In June 2024, Sysmex Astrego AB was awarded the Longitude Prize on Antimicrobial Resistance, receiving an £8 million prize for its transformative diagnostic technology. The company was recognized for its breakthrough point-of-care testing system, which utilizes nanofluidic technology to detect bacterial presence in a urine sample within 15 minutes and determine antibiotic susceptibility in approximately 45 minutes. This rapid testing capability is designed to support healthcare providers in making informed treatment decisions quickly, thereby reducing the prescription of ineffective antibiotics and combating the global challenge of antimicrobial resistance.
• In June 2024, Winx Health introduced a new "Test + Treat" solution aimed at streamlining the diagnosis and management of urinary tract infections. The offering includes a package of three diagnostic tests combined with a digital platform that connects users directly to physicians for immediate clinical evaluation. If a test result is positive, the service facilitates same-day prescription treatments, addressing the critical need for accessible and affordable care. This product introduction seeks to alleviate the significant challenges patients often face in scheduling in-person appointments and obtaining timely medical intervention for acute symptoms.
• In January 2024, Vivoo launched a new digital at-home testing product for urinary tract infections during the Consumer Electronics Show. The product utilizes a urine test strip and a mobile application powered by deep learning image processing technology to provide clinical-grade results in just two minutes. This innovation allows users to scan the test strip with their smartphone, ensuring accurate readings and enabling data digitalization for easy sharing with healthcare professionals. The launch aims to address a significant market gap by improving accessibility to diagnostics and facilitating timely medical consultations for the millions of individuals affected by these infections annually.

Key Market Players

• QIAGEN NV
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthcare GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• BIOMÉRIEUX
• T2 Biosystems, Inc

By Type	By End use	By Region
Urethritis Cystitis Pyelonephritis	General Practitioners (GPs) Urologists Urogynecologists Hospital Laboratories Reference Laboratories Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Urinary Tract Infection Testing Market, By Type:

• Urethritis
• Cystitis
• Pyelonephritis

• Urinary Tract Infection Testing Market, By End use:

• General Practitioners (GPs)
• Urologists
• Urogynecologists
• Hospital Laboratories
• Reference Laboratories
• Others

• Urinary Tract Infection Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE